SCHEMBL23620439

SCHEMBL23620439

CCOC(=O)c1cnc(Cl)nc1NC1CCCC(O)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 3/20 0.58
JAK3 P52333 3/20 0.58
MAPK8 P45983 13/20 0.52
MAPK9 P45984 5/20 0.52
NR2F2 P24468 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.51
NPC1 O15118 1/20 0.51
S1PR2 O95136 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
XBP1 P17861 1/20 0.51
RAB9A P51151 1/20 0.51
PPP1CA P62136 1/20 0.51
KMT2A Q03164 1/20 0.51
SYK P43405 1/20 0.48
PDE4B Q07343 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501857 1.00 JAK1 (0.58) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL23611090 0.94 JAK3 (0.57) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL29502041 0.94 JAK3 (0.57) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL761164 0.91 NR2F2 (0.60) JAK1JAK3MAPK8NR2F2NPSR1
SCHEMBL23620546 0.90 SYK (0.52) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL29501946 0.90 SYK (0.52) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL29501963 0.90 SYK (0.52) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL23620380 0.90 SYK (0.52) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL30906009 0.90 SYK (0.52) JAK1JAK3MAPK8MAPK9NR2F2
SCHEMBL26159809 0.90 SYK (0.52) JAK1JAK3MAPK8MAPK9NR2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
CN-113121538-B Furan derivative and application thereof in medicine 成都百裕制药股份有限公司 2023-04-21 CN disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
CN-113121538-A Furan derivative and application thereof in medicine 成都百裕制药股份有限公司 2021-07-16 CN disclosed
WO-2021136462-A1 FURAN DERIVATIVES AND APPLICATION THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 JAK1 593/4885JAK3 599/4885MAPK8 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.